Efficacy and safety of povorcitinib for extensive vitiligo: 52-week results from a double-blinded, placebo-controlled, dose-ranging phase 2b study

被引：0
|
作者：
Pandya, Amit G. [1 ,2 ]
Ezzedine, Khaled [3 ,4 ]
Passeron, Thierry [5 ,6 ]
van Geel, Nanja [7 ]
Brown, Kurt [8 ]
Santos, Leandro [8 ]
Erskine, Lois [8 ]
Wagya, Kofi [8 ]
Blauvelt, Andrew [9 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX USA
[2] Palo Alto Fdn Med Grp, Sunnyvale, CA USA
[3] Henri Mondor Univ Hosp, Paris, France
[4] Univ Paris Est Creteil Val de Marne, Paris, France
[5] Univ Cote Azur, Ctr Hosp Univ Nice, Nice, France
[6] Univ Cote Azur, INSERM U1065, C3M, Nice, France
[7] Ghent Univ Hosp, Ghent, Belgium
[8] Incyte Corp, Wilmington, DE USA
[9] Oregon Med Res Ctr, Portland, OR USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷
关键词：
JAK1; inhibitor; oral administration; INCB054707; repigmentation; vitiligo;
D O I：
10.1093/bjd/ljae266.094
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
721
引用
收藏
页数：2
相关论文
共 50 条
  • [41] EFFICACY AND SAFETY OF TABALUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM 2 PHASE 3, 52-WEEK, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIALS
    Isenberg, D.
    Merrill, J.
    Hoffman, R.
    Linnik, M.
    Morgan-Cox, M.
    Veenhuizen, M.
    Iikuni, N.
    Dickson, C.
    Silk, M.
    Wallace, D.
    Doerner, T.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 141 - 141
  • [42] Lebrikizumab, a high-affinity interleukin-13 inhibitor, improves clinical manifestations in moderate to severe atopic dermatitis: Time course of response from a randomized, double-blinded, placebo-controlled, dose-ranging, phase 2b study
    Guttman-Yassky, Emma
    Blauvelt, Andrew
    Eichenfield, Lawrence F.
    Paller, Amy
    Armstrong, April W.
    Drew, Janice S.
    Gopalan, Ramanan
    Simpson, Eric L.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB63 - AB63
  • [43] EFFICACY AND SAFETY OF LY2951742 IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY IN PATIENTS WITH MIGRAINE
    Skljarevski, V.
    Oakes, T.
    Ferguson, M.
    Zhang, Q.
    Martinez, J.
    Johnson, K.
    Schacht, A.
    Due, M.
    Goadsby, P.
    Dodick, D.
    [J]. CEPHALALGIA, 2016, 36 : 42 - 42
  • [44] Efficacy and safety of LY2951742 in a randomized, double-blind, placebo-controlled, dose-ranging study in patients with migraine
    Oakes, T.
    Zhang, Q.
    Ferguson, M.
    Skljarevski, V
    Martinez, J. M.
    Johnson, K. W.
    Schacht, A. L.
    Due, M. R.
    Goadsby, P.
    Dodick, D. W.
    [J]. HEADACHE, 2016, 56 : 68 - 68
  • [45] A double-blinded, randomized, placebo-controlled pilot study of the safety and efficacy of myobloc (Botulinum toxin type B)-purified neurotoxin complex for the treatment of crow's feet: A double-blinded, placebo-controlled trial
    Baumann, L
    Slezinger, A
    Vujevich, J
    Halem, M
    Bryde, J
    Black, L
    Duncan, R
    [J]. DERMATOLOGIC SURGERY, 2003, 29 (05) : 508 - 515
  • [46] Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide
    Althof, Stanley
    Derogatis, Leonard R.
    Greenberg, Sally
    Clayton, Anita H.
    Jordan, Robert
    Lucas, Johna
    Spana, Carl
    [J]. JOURNAL OF SEXUAL MEDICINE, 2019, 16 (08): : 1226 - 1235
  • [47] The efficacy and safety of macitentan in Fontan-palliated patients: results of the 52-week randomised, placebo-controlled RUBATO trial
    Clift, P.
    Berger, F.
    Sondergaard, L.
    Antonova, P.
    Disney, P.
    Nicolarsen, J.
    Thambo, J. -B.
    Pajak, L. Tomkiewicz
    Wang, J. -K.
    Jensen, A. Schophuus
    Burgess, G.
    Efficace, M.
    Friberg, M.
    Lassen, C.
    d'Udekem, Y.
    [J]. EUROPEAN HEART JOURNAL, 2022, 43 : 1560 - 1560
  • [48] A Randomized, Double-Blinded, Placebo-Controlled, Ascending Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of ®Xmab 7195
    Gershman, A.
    Goldwater, R.
    Foster, P.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [49] A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis
    Gupta, AK
    Leonardi, C
    Stoltz, RR
    Pierce, PF
    Conetta, B
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2005, 19 (04) : 437 - 443
  • [50] A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin in adults with severe to very-severe alopecia areata
    Rosmarin, David
    Sadick, Neil
    Rodgers, Timothy G.
    Lain, Edward
    Osman, Lawrence
    Schleicher, Stephen
    Reich, Adam
    Szepietowski, Jacek C.
    Owczarczyk-Saczonek, Agnieszka
    Baran, Wojciech
    Kwiek, Bartlomiej
    Torz, Michal
    Zdybski, Jacek
    Chaudhry, Sohail
    Lee, Zachary
    Xu, Heng
    Liu, Yi
    Lewis, Brian
    Mellskog, Katie
    Elko-Simms, Lucinda M.
    Fanton, Christie
    Tagliaferri, Mary
    Zalevsky, Jonathan
    Lynde, Charles W.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
12345